PT - JOURNAL ARTICLE AU - Coggins, Si’Ana A. AU - Laing, Eric D. AU - Olsen, Cara H. AU - Goguet, Emilie AU - Moser, Matthew AU - Jackson-Thompson, Belinda M. AU - Samuels, Emily C. AU - Pollett, Simon D. AU - Tribble, David R. AU - Davies, Julian AU - Illinik, Luca AU - Hollis-Perry, Monique AU - Maiolatesi, Santina E. AU - Duplessis, Christopher A. AU - Ramsey, Kathleen F. AU - Reyes, Anatalio E. AU - Alcorta, Yolanda AU - Wong, Mimi A. AU - Wang, Gregory AU - Ortega, Orlando AU - Parmelee, Edward AU - Lindrose, Alyssa R. AU - Snow, Andrew L. AU - Malloy, Allison M.W. AU - Letizia, Andrew G. AU - Powers, John H. AU - Burgess, Timothy H. AU - Broder, Christopher C. AU - Mitre, Edward TI - Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers AID - 10.1101/2021.06.25.21259544 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.25.21259544 4099 - http://medrxiv.org/content/early/2021/07/02/2021.06.25.21259544.short 4100 - http://medrxiv.org/content/early/2021/07/02/2021.06.25.21259544.full AB - Background mRNA COVID-19 vaccines are playing a key role in controlling the COVID-19 pandemic. The relationship between post-vaccination symptoms and strength of antibody responses is unclear.Objective To determine whether adverse effects caused by vaccination with the Pfizer/BioNTech BNT162b2 vaccine are associated with the magnitude of vaccine-induced antibody levels.Design Single center, prospective, observational cohort study.Setting Participants worked at Walter Reed National Military Medical Center and were seen monthly at the Naval Medical Research Center Clinical Trials Center.Participants Generally healthy adults that were not severely immunocompromised, had no history of COVID-19, and were seronegative for SARS-CoV-2 spike protein prior to vaccination.Measures Severity of vaccine-associated symptoms was obtained through participant completed questionnaires. Testing for IgG antibodies against SARS-CoV-2 spike protein and receptor binding domain was conducted using microsphere-based multiplex immunoassays.Results 206 participants were evaluated (69.4% female, median age 41.5 years old). We found no correlation between vaccine-associated symptom severity scores and vaccine-induced antibody titers one month after vaccination. We also observed that 1) post-vaccination symptoms were inversely correlated with age and weight and more common in women, 2) systemic symptoms were more frequent after the second vaccination, 3) high symptom scores after first vaccination were predictive of high symptom scores after second vaccination, and 4) older age was associated with lower titers.Limitations Study only observes antibody responses and consists of healthy participants.Conclusions Lack of post-vaccination symptoms following receipt of the BNT162b2 vaccine does not equate to lack of vaccine-induced antibodies one month after vaccination. This study also suggests that it may be possible to design future mRNA vaccines that confer robust antibody responses with lower frequencies of vaccine-associated symptoms.Funding This study was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed by the Uniformed Services University of the Health Sciences (USUHS) through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). This project has been funded by the Defense Health Program, U.S. DoD, under award HU00012120067. Project funding for JHP was in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The funding bodies have had no role in the study design or the decision to submit the manuscript for publication.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed by the Uniformed Services University of the Health Sciences (USUHS) through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). This project has been funded by the Defense Health Program, U.S. DoD, under award HU00012120067. Project funding for JHP was in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The funding bodies have had no role in the study design or the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study protocol was approved by the Uniformed Services University of the Health Sciences Institutional Review Board (FWA 00001628; DoD Assurance P60001) in compliance with all applicable Federal regulations governing the protection of human participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the first (S.C.) and corresponding (E.M.) authors upon request.